Destiny Pharma plc
("Destiny Pharma" or the "Company")
Grant of share options
Brighton, United Kingdom - 21st January 2021 - Destiny Pharma plc (AIM: DEST, "the Company") a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces the following options ("Options") over a total of 180,436 ordinary shares of 1 pence in the Company have been granted under the Destiny Pharma plc 2020 Long Term Incentive Plan (the "Plan") to the following Directors and PDMRs in respect of bonuses due for the financial year ended 31 December 2020:
| Name | Position | Total number of Options granted under award | Total Options held after the grant |
| Neil Clark | Chief Executive Officer | 53,053 | 1,156,745 |
| Shaun Claydon | Chief Financial Officer | 39,230 | 700,768 |
| William Love | Chief Scientific Officer | 45,095 | 1,176,000 |
| Jesus Gonzalez | Chief Medical Officer | 43,058 | 492,242 |
�
The Options have been granted with a nominal exercise price and will vest on 21 January 2023.
�
Enquiries:
| Destiny Pharma plc | +44 (0) 1273 704 440 |
| Neil Clark (Chief Executive Officer) | � |
| finnCap Limited - Nominated Adviser and Joint Broker | +44 (0) 20 7220 0500 |
| Geoff Nash / Kate Bannatyne / Charlie Beeson (Corporate Finance) | � |
| WG Partners LLP - Joint Broker | +44 (0) 20 3705 9330 |
| Nigel Barnes / Claes Sp�ng / Nigel Birks / Andrew Craig | � |
| Optimum Strategic Communications | +44 (0) 203 174 1789 |
| Mary Clark / Shabnam Bashir / Manel Mateus � � | � |
The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.
�
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of�C. difficile�infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which is in a Phase 2b clinical trial targeting the prevention of post-surgical Staphylococcal hospital including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.
�
For further information, please visit�https://www.destinypharma.com
�
�
�
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
| 1.��������������� | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Neil Clark |
| 2.��������������� | Reason for the Notification | |
| a) | Position/status | Chief Executive Officer |
| b) | Initial notification/Amendment | Initial notification |
| 3.���� | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Destiny Pharma plc |
| b) | LEI | 213800O9WH9Z38EHAC95 |
| 4.���� | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the Financial instrument, type of instrument | Grant of award of options over ordinary shares of 1 pence each ("Ordinary Shares") under the 2020 Destiny Pharma plc Long Term Incentive Plan. � |
| Identification code | DEST� ��� GB00BDHSP575 | |
| b) | Nature of the transaction | Grant of award of options over Ordinary Shares under the 2020 Destiny Pharma plc Long Term Incentive Plan. |
| c) | Price(s) and volume(s) | 1 pence�exercise price per Ordinary Share �53,053 Ordinary Shares |
| d) | Aggregated information: Aggregated volume Price | � See 4c) above� � |
| e) | Date of the transaction | 21 January 2021 |
| f) | Place of the transaction | London Stock Exchange, AIM Market |
�
| 1.��������������� | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Shaun Claydon |
| 2.��������������� | Reason for the Notification | |
| a) | Position/status | Chief Financial Officer |
| b) | Initial notification/Amendment | Initial notification |
| 3.���� | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Destiny Pharma plc |
| b) | LEI | 213800O9WH9Z38EHAC95 |
| 4.���� | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the Financial instrument, type of instrument | Grant of award of options over ordinary shares of 1 pence each ("Ordinary Shares") under the 2020 Destiny Pharma plc Long Term Incentive Plan. � |
| Identification code | DEST� ��� GB00BDHSP575 | |
| b) | Nature of the transaction | Grant of award of options over Ordinary Shares under the 2020 Destiny Pharma plc Long Term Incentive Plan. |
| c) | Price(s) and volume(s) | 1 pence�exercise price per Ordinary Share 39,230 Ordinary Shares |
| d) | Aggregated information: Aggregated volume Price | � See 4c) above� � |
| e) | Date of the transaction | 21 January 2021 |
| f) | Place of the transaction | London Stock Exchange, AIM Market |
�
�
�
| 1.��������������� | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Bill Love |
| 2.��������������� | Reason for the Notification | |
| a) | Position/status | Chief Scientific Officer |
| b) | Initial notification/Amendment | Initial notification |
| 3.���� | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Destiny Pharma plc |
| b) | LEI | 213800O9WH9Z38EHAC95 |
| 4.���� | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the Financial instrument, type of instrument | Grant of award of options over ordinary shares of 1 pence each ("Ordinary Shares") under the 2020 Destiny Pharma plc Long Term Incentive Plan. � |
| Identification code | DEST� ��� GB00BDHSP575 | |
| b) | Nature of the transaction | Grant of award of options over Ordinary Shares under the 2020 Destiny Pharma plc Long Term Incentive Plan. |
| c) | Price(s) and volume(s) | 1 pence�exercise price per Ordinary Share 45,095 Ordinary Shares |
| d) | Aggregated information: Aggregated volume Price | � See 4c) above� � |
| e) | Date of the transaction | 21 January 2021 |
| f) | Place of the transaction | London Stock Exchange, AIM Market |
�
�
�
| 1.��������������� | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Jesus Gonzalez |
| 2.��������������� | Reason for the Notification | |
| a) | Position/status | Chief Medical Officer |
| b) | Initial notification/Amendment | Initial notification |
| 3.���� | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Destiny Pharma plc |
| b) | LEI | 213800O9WH9Z38EHAC95 |
| 4.���� | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the Financial instrument, type of instrument | Grant of award of options over ordinary shares of 1 pence each ("Ordinary Shares") under the 2020 Destiny Pharma plc Long Term Incentive Plan. � |
| Identification code | DEST� ��� GB00BDHSP575 | |
| b) | Nature of the transaction | Grant of award of options over Ordinary Shares under the 2020 Destiny Pharma plc Long Term Incentive Plan. |
| c) | Price(s) and volume(s) | 1 pence�exercise price per Ordinary Share 43,058 Ordinary Shares |
| d) | Aggregated information: Aggregated volume Price | � See 4c) above� � |
| e) | Date of the transaction | 21 January 2021 |
| f) | Place of the transaction | London Stock Exchange, AIM Market |
�
�